CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor ...
Phase 1, Phase 2
Salt Lake City, Utah, United States and 84 other locations
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors....
Phase 1
Salt Lake City, Utah, United States and 15 other locations
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor...
Phase 2, Phase 3
Salt Lake City, Utah, United States and 957 other locations
This study will test the safety of a drug called PF-08046052/SGN-EGFRd2 in participants with advanced solid tumors. It will also study the s...
Phase 1
Salt Lake City, Utah, United States and 22 other locations
of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors...
Phase 1, Phase 2
West Valley City, Utah, United States of America and 10 other locations
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab ver...
Phase 3
Salt Lake City, Utah, United States and 427 other locations
versus a fluoropyrimidine/bevacizumab alone as assessed by molecular response which is based on changes in circulating tumor (ct)DNA. The...
Phase 2, Phase 3
Salt Lake City, Utah, United States and 42 other locations
and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers...
Phase 2
Salt Lake City, Utah, United States and 65 other locations
treatment) or* are metastatic (has spread to other parts of the body).This includes (but limited to) the following cancer types:* Non-Small...
Phase 1
West Valley City, Utah, United States of America and 6 other locations
without biological agent and monalizumab (IPH2201) with biological agent administered to participants with recurrent or metastatic colorectal cancer...
Phase 1, Phase 2
Salt Lake City, Utah, United States and 48 other locations
Clinical trials
Research sites
Resources
Legal